Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders
- 1st Edition - October 25, 2024
- Latest edition
- Editors: Gabriele De Rubis, Ronan MacLoughlin, Hélder A. Santos, Saritha Shetty, Divya Suares, Kamal Dua
- Language: English
Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders focuses on 3D printing, bioprinting, microfluidics, organ-on-a-chip systems, and molecu… Read more
Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders focuses on 3D printing, bioprinting, microfluidics, organ-on-a-chip systems, and molecular modeling. The book, written by a team of leading experts in the field, is an essential resource for anyone interested in the future of CRD treatment. Chapters discuss the emerging therapeutic approaches for CRDs, including biologicals and phytoceuticals. Core chapters of the book then cover the application of 3D printing, bioprinting, microfluidics, organ-on-a-chip systems, and molecular modeling to different CRDs. The book concludes with a discussion of the current clinical trials and future prospects for the management of CRDs.
This is a valuable resource for researchers, clinicians, and other healthcare professionals who are interested in the latest technological advances in the field of CRDs. It will also be of interest to students and scientists working in the fields of pharmaceutical sciences, microfluidics, bioinformatics, drug design, drug delivery, and 3D printing.
This is a valuable resource for researchers, clinicians, and other healthcare professionals who are interested in the latest technological advances in the field of CRDs. It will also be of interest to students and scientists working in the fields of pharmaceutical sciences, microfluidics, bioinformatics, drug design, drug delivery, and 3D printing.
- Provides the most recent and updated perspectives and challenges in the management of chronic respiratory disorders
- Covers exciting new technologies such as 3D printing, bioprinting, microfluidics, organ-on-a-chip systems, and molecular modelling
- Includes the most recent information on the development of advanced drug delivery systems for the treatment of chronic respiratory disorders
Researchers and graduate students of Pharmaceutical Sciences, Biotechnology, Immunology, Medical & Health Sciences, Pharmaceutical & translational medical research
1. Preface
2. Introduction to chronic respiratory disorders
3. Current approaches for the treatment of chronic respiratory disorders and limitations
4. Emerging therapeutics in the treatment of chronic respiratory disorders
5. Advanced drug delivery systems in the treatment of chronic respiratory disorders including targeted drug delivery, inhalation therapy, and nanotechnology-based drug delivery systems and its applications
6. 3D Printing, 3D-printed Scaffolds and Bioprinting in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems
7. Microfluidics in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems
8. Organ-on-a-chip in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems
9. Molecular modelling and computer-aided drug design in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems
10. Current clinical trials, future prospects, and challenges in the management of chronic respiratory disorders
2. Introduction to chronic respiratory disorders
3. Current approaches for the treatment of chronic respiratory disorders and limitations
4. Emerging therapeutics in the treatment of chronic respiratory disorders
5. Advanced drug delivery systems in the treatment of chronic respiratory disorders including targeted drug delivery, inhalation therapy, and nanotechnology-based drug delivery systems and its applications
6. 3D Printing, 3D-printed Scaffolds and Bioprinting in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems
7. Microfluidics in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems
8. Organ-on-a-chip in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems
9. Molecular modelling and computer-aided drug design in the diagnosis and treatment of chronic respiratory disorders and its application to advanced drug delivery systems
10. Current clinical trials, future prospects, and challenges in the management of chronic respiratory disorders
- Edition: 1
- Latest edition
- Published: October 25, 2024
- Language: English
GR
Gabriele De Rubis
Gabriele holds a Bachelor's Degree in Biotechnology ("La Sapienza" University of Rome, Italy) and a Master's
degree in Genetic Sciences and Technologies (University of Sannio, Benevento, Italy). He has just
completed a PhD in Pharmacy (thesis under examination) at the Discipline of Pharmacy, Graduate School
of Health, UTS, with a thesis on the development of advanced drug delivery systems for respiratory diseases.
Gabriele has extensive experience as an industry-based researcher, particularly in the setup and
evaluation of animal (mouse and rat) models of cancer and inflammatory diseases and in the preclinical
in vivo testing of the safety, efficacy and pharmacokinetic properties of novel anti-cancer and anti-inflammatory
drugs.
Gabriele's current expertise and research interest cover the in vitro advanced
drug delivery of phytoceuticals and nucleic acid-based therapeutics (decoy oligodeoxynucleotides,
miRNAs) for the treatment of respiratory inflammatory diseases and lung cancer.
Affiliations and expertise
University of Technology Sydney, AustraliaRM
Ronan MacLoughlin
Dr Ronan MacLoughlin, PhD MBS, is currently director of Research and Development, Science and Emerging Technologies in Aerogen limited and Irish medical device company specializing in respiratory drug delivery. He has more than 25 years of experience in the design and development of aerosol drug delivery systems and drug/device combination products. He currently has more than 120 articles, and multiple conference presentations and conference papers combined with several patents. He holds the position of adjunct associate professor in Trinity College Dublin’s (Ireland) Department of Pharmaceutics and Pharmaceutical Technology, honorary Senior Lecturer in the Royal College of Surgeons Ireland (RCSI), nonexecutive director on the board of several startup and scaling Med tech and pharmaceutical companies. Additionally, he is currently chair of the pediatric and cystic fibrosis working group within the International Society for aerosols in medicine. In 2024 he was honored with the Thomas T Mercer award, recognizing Dr MacLoughlin’s excellence in the areas of pharmaceutical aerosols and inhalable materials.development of drug delivery systems and drug device combinations, he has >220 collaborative publications,
as well as 12 granted patents.
His most recent focus has been on enabling several clinical programs making use of aerosolised prophylactics
and therapeutics for COVID-19, and his work on delivery of inhaled vaccines has resulted in the
world’s first approval for an orally inhaled vaccine for COVID-19 (Convidecia Air). His contribution to the
state of the art in fugitive medical and patient-derived aerosols was central to the evolution of several
critical care consensus statements around the safe use of aerosol therapy during the COVID-19 pandemic.
Affiliations and expertise
Aerogen pty Ltd, IrelandHS
Hélder A. Santos
Prof. Santos (D.Sc. Tech., Chem. Eng.) is a Full Professor in Department of Biomedical Engineering at the University of Groningen. He is also Research Director at the University of Helsinki, Faculty of Pharmacy. Prof. Santos is also the co-founder of the startups Capsamedix Oy and Medixmicro Oy, and Coordinator of MSCA-ITN P4 FIT network in tendon repair (~4.1 m€). He holds Visiting Professorships at the Shanghai Jiao Tong University School of Medicine and University of Tartu. Prof. Santos research interests include the development of nanoparticles/nanomedicines and biomaterials for biomedical applications, particularly cancer and heart diseases. His lab makes the unique bridge between medical engineering, pharmaceutical nanotechnology and tissue engineering by combining unique techniques to develop novel therapeutic formulations for translation into the clinic. He is also in Editorial board member of several international journals, and Associate Editor of Nano Select, Smart Materials in Medicine, and Drug Delivery and Translational Research, among others. Prof. Santos has received prestigious awards/grants, for example, the "Talent Prize in Science" in 2010 attributed by the Portuguese Government, ERC Starting Grant in 2013 and ERC Proof-of-Concept Grant in 2018, Young Researcher Award in 2013 attributed by Faculty of Pharmacy, the Academy of Finland Award for Social Impact in 2016, and the CRS Young Investigator Award 2021.
Affiliations and expertise
Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland; Department of Biomedical Engineering, University Medical Center Groningen/University of Groningen, Groningen, The NetherlandsSS
Saritha Shetty
Dr. Saritha Shetty
Associate Professor, Pharmaceutics
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management
SVKM’s NMIMS, V.L.Mehta
Vile Parle (west), Mumbai, has a research experience of over 16 years working in the area of drug delivery and
analytical method development. Before joining academics, she served as Scientist at Syngene International.
Pvt. Ltd. (A Biocon Group), Bangalore, India. During this tenure, she has completed projects of
major client like Baxter ACC – (Baxter Anesthesia Critical Care, USA) for analytical method development
and validation using HPLC and GC. Dr. Shetty has her research interest in areas of developing drug delivery
systems for infectious diseases. She has developed novel and effective formulations for topical and
transdermal systems, mucoadhesive systems for respiratory and oral delivery.
Edit
Affiliations and expertise
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, IndiaDS
Divya Suares
Dr. Divya Suares
Assistant Professor, Pharmaceutics
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management,
SVKM's NMIMS, V.L. Mehta Road has a
search experience of over 14 years in the area of drug delivery. Dr. Divya completed her Bachelor’s Degree
in Pharmacy and Master’s Degree in Pharmaceutics from Rajiv Gandhi University of Health Sciences,
India. She completed her Doctor of Philosophy in Pharmaceutical Sciences from NMIMS deemed-to-be
University, wherein her research project involved development and evaluation of lipid based formulation
of Rosuvastatin. Dr. Divya’s research interest encompass the development of drug delivery systems via
the oral, topical, intranasal route for the management of various disorders, development of effective
formulations for wound healing and pediatric-friendly drug delivery systems.
Edit
Affiliations and expertise
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, IndiaKD
Kamal Dua
Dr. Kamal Dua is a renowned researcher in pharmaceutics and drug delivery, with dual doctorates in Pharmaceutical Sciences and Immunology & Microbiology. As an Associate Professor at the University of Technology Sydney, he specializes in managing chronic inflammatory diseases, focusing on nanocarrier-based therapies. He also serves as an Adjunct Assistant Professor at the University of Alberta and holds multiple international adjunct positions. With over 190 peer-reviewed publications and more than 16,000 citations, Dr. Dua is recognized as a leading figure in toxicology and pharmaceutical sciences in Australia. His innovative teaching combines traditional and modern methods, fostering a dynamic learning environment. A recipient of numerous accolades, including being named one of Australia's Top 250 researchers in 2024, he is committed to mentoring emerging scientists and advancing novel therapeutic solutions that aim to transform clinical practices and improve patient outcomes worldwide.
Affiliations and expertise
Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, AustraliaRead Technological Advances and Innovations in the Treatment of Chronic Respiratory Disorders on ScienceDirect